Change Language

Select Language

Europe Dry Eye Syndrome Market to Reach US$ 940.59 Million by 2027, Impelled by Rising Geriatric Population

Published on Mar 02, 2022

As per the latest report by IMARC Group, titled “Europe Dry Eye Syndrome Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2022-2027,” the Europe dry eye syndrome market size reached US$ 677Million in 2021.Dry eye syndrome (DES), also known as keratoconjunctivitis sicca (KCS), is a medical condition that occurs due to the lack of moisture or lubrication on the surface of the eye. It is characterized by symptoms, including irritation, redness, discharge, fatigued eyes, and blurred vision. It is caused by various reasons such as hormone changes, autoimmune disease, inflamed eyelid glands, allergic eye disease, extensive computer usage, and medication that disrupt the healthy tear film. However, dry eye syndromecan be treated through administering artificial tears, medications, lacrimal plugs, and surgeries.

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Europe Dry Eye Syndrome Market Trends:

The rising geriatric population, which is more susceptible to chronic eye diseases, is one of the key factors driving the market growth. Dry eye syndrome is also caused by various other medical conditions, such as Sjogren’s syndrome, lupus, scleroderma, rheumatoid arthritis, sarcoidosis, thyroid disorders, and diabetes, which is highly prevalent among elderly patients. In addition, sedentary lifestyles and a lack of physical activities of the masses are leading to increased oxidative stress and reduced mucin expression in the eyes. As a result, patients and healthcare providers are widely adopting corticosteroid drugs to effectively treat dry eye syndrome,. Furthermore, the improving diagnostic technologies, rising healthcare expenditure capacities of consumers, and increasing utilization of smartphones, laptops and television among the masses leading to prolonged and excessive screen time are some of the other factors creating a positive market outlook across the region. Looking forward, IMARC Group expects the market value to reach US$ 940.59Million by 2027, exhibiting a CAGR of 5.55% during the forecast period (2022-2027).

Market Summary:

  • Based on the disease type, the market has been bifurcatedinto evaporative and aqueous dry eye syndrome.
  • On the basis ofthe drug type, the market has been segregated into anti-inflammatory drugs, lubricant eye drops, and autologous serum eye drops.
  • Based on the product, the market has been categorizedinto liquid drops, gel, liquid wipes, eye ointment, and others.
  • The market has been segmented based on the distribution channelinto hospital, retail, and online pharmacies.
  • On the geographical front, the market has been divided into Germany, France, the United Kingdom, Italy, Spain, and others.
  • The competitive landscape of the industry has also been examined,along with the profiles of the key players.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US

30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800


Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )

Drop us an email at